Peter D. Suzdak, PhD

Dr. Suzdak is co-founder of Cardioxyl Pharmaceuticals. Dr. Suzdak is a Research and Development Executive with more than 17 years experience in U.S. and European based Pharmaceutical companies. Dr. Suzdak has held multiple positions in the Pharmaceutical industry over the past 17 years. Dr. Suzdak has established multiple highly successful Research and Development organizations which have resulted in the filing of 14 IND’s and 3 NDA/sNDA’s. Dr. S... more

Dr. Suzdak is co-founder of Cardioxyl Pharmaceuticals. Dr. Suzdak is a Research and
Development Executive with more than 17 years experience in U.S. and European based
Pharmaceutical companies. Dr. Suzdak has held multiple positions in the Pharmaceutical
industry over the past 17 years. Dr. Suzdak has established multiple highly successful
Research and Development organizations which have resulted in the filing of 14 IND’s and
3 NDA/sNDA’s. Dr. Suzdak co-founded Artesian Therapeutics, a cardiovascular focused
drug discovery company, as President/CEO and raised $15M in venture capital financing. In
October 2005, Artesian Therapeutics was acquired by Cardiome Pharma. Prior to joining
Artesian Therapeutics, Dr. Suzdak was most recently at Guilford Pharmaceuticals from 1995
to 2002.  During his tenure as Vice President of Research, then Senior Vice President of
Research and Development, Dr. Suzdak was responsible for all Pharmaceuticals Drug
Discovery, Preclinical Development and Clinical Development activities at Guilford. Dr.
Suzdak was responsible for establishing an integrated Drug Discovery and development
function at Guilford and building an extensive technology and intellectual property platform
around multiple novel biological targets.
Prior to joining Guilford, Dr. Suzdak held various positions at Novo-Nordisk A/S in
Copenhagen Denmark from 1988 to 1995, including Director of Neurobiology Research. Dr.
Suzdak was involved in multiple Drug Discovery and Development collaborations with
major Pharmaceutical companies in the U.S. and Europe, including Abbott which resulted in
the successful discovery, clinical development, approval and marketing of the novel anti-
epileptic Gabatril®. Prior thereto, Dr. Suzdak was a Pharmacology Research Associate in
the Clinical Neuroscience Branch of the National Institute of Mental Health in Bethesda, in
the laboratory of Dr. Steven M. Paul from 1985 to 1988. Dr. Suzdak received his Ph.D. in
Pharmacology from the University of Connecticut and a B.S. in Pharmacy from St. Johns
University. less